G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 14.89 USD -3% Market Closed
Market Cap: 923.6m USD

GH Research PLC
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

GH Research PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Cash & Cash Equivalents
$100.8m
CAGR 3-Years
-29%
CAGR 5-Years
189%
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Cash & Cash Equivalents
$432.1m
CAGR 3-Years
-3%
CAGR 5-Years
-13%
CAGR 10-Years
-2%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Cash & Cash Equivalents
$1.3B
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Cash & Cash Equivalents
$79.8m
CAGR 3-Years
10%
CAGR 5-Years
-1%
CAGR 10-Years
8%
Cosmo Pharmaceuticals NV
SIX:COPN
Cash & Cash Equivalents
€44.3m
CAGR 3-Years
-41%
CAGR 5-Years
-12%
CAGR 10-Years
1%
Ovoca Bio PLC
LSE:OVB
Cash & Cash Equivalents
€2.5m
CAGR 3-Years
-28%
CAGR 5-Years
-24%
CAGR 10-Years
-10%
No Stocks Found

GH Research PLC
Glance View

Market Cap
923.6m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
2.94 USD
Overvaluation 80%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
100.8m USD

Based on the financial report for Dec 31, 2024, GH Research PLC's Cash & Cash Equivalents amounts to 100.8m USD.

What is GH Research PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
189%

Over the last year, the Cash & Cash Equivalents growth was 29%. The average annual Cash & Cash Equivalents growth rates for GH Research PLC have been -29% over the past three years , 189% over the past five years .

Back to Top